{"id":"W2561439167","doi":"10.1093/annonc/mdw665","title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement; University of Toronto; Sunnybrook Health Science Centre; Canadian Red Cross Society","funders":"Eisai; Genentech; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; F. Hoffmann-La Roche","keywords":"Medicine; Bevacizumab; Adjuvant; Adjuvant therapy; Triple-negative breast cancer; Breast cancer; Oncology; Randomized controlled trial; Internal medicine; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001214114,0.0001890177,0.0007795194,0.00006340493,0.00007241716,0.000003405245,0.000165514,0.0001480883,0.00001779558],"category_scores_gemma":[0.0006985716,0.0001049355,0.0001549127,0.0001669577,0.000423687,0.000008843816,0.0001148773,0.00008255465,3.047692e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000387136,"about_ca_system_score_gemma":0.0003596779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001173687,"about_ca_topic_score_gemma":0.0003118782,"domain_scores_codex":[0.997764,0.0007664369,0.0007159463,0.0003453674,0.0001547139,0.0002535179],"domain_scores_gemma":[0.9981056,0.0006576296,0.0006443305,0.000238691,0.0003122044,0.00004152313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.784111,0.0003681135,0.0003682331,0.000003207569,0.0004287209,0.000001676096,0.0007032183,0.000006285827,0.0187979,0.00001482967,0.0001626134,0.1950342],"study_design_scores_gemma":[0.939009,0.005587197,0.02141176,0.00008310435,0.0000985372,0.000008527339,0.0001088173,0.00001205794,0.03307514,0.0000843391,0.0003888647,0.0001326991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925122,0.001489143,0.00001786434,0.003977019,0.0001668976,0.001130266,0.0003891816,0.000004192451,0.0003132835],"genre_scores_gemma":[0.9966885,0.002697848,0.00006892643,0.0001688204,0.0001362676,0.0001279574,0.00001771648,0.00001214171,0.00008180482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1949015,"threshold_uncertainty_score":0.4279144,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06968499473878104,"score_gpt":0.4052475702943823,"score_spread":0.3355625755556013,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}